Thompson Siegel & Walmsley LLC Buys 1,029,770 Shares of Perrigo Company plc $PRGO

Thompson Siegel & Walmsley LLC boosted its stake in Perrigo Company plc (NYSE:PRGO) by 28.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,658,601 shares of the company’s stock after acquiring an additional 1,029,770 shares during the period. Perrigo accounts for about 1.1% of Thompson Siegel & Walmsley LLC’s holdings, making the stock its 22nd biggest position. Thompson Siegel & Walmsley LLC’s holdings in Perrigo were worth $64,848,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geneos Wealth Management Inc. raised its position in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. Kestra Investment Management LLC raised its position in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the period. Jones Financial Companies Lllp raised its position in shares of Perrigo by 89.1% in the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after purchasing an additional 838 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the period. Finally, CWM LLC raised its position in shares of Perrigo by 230.0% in the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after purchasing an additional 1,527 shares during the period. Institutional investors own 95.91% of the company’s stock.

More Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks Research raised its estimates for Perrigo’s Q3 2026, Q4 2026, Q2 2027, and Q4 2027 earnings, suggesting some expected improvement in later periods. Perrigo estimate updates
• Neutral Sentiment: The analyst kept a Hold rating on Perrigo, indicating no major change in overall stance despite the forecast revisions. Perrigo estimate updates
• Negative Sentiment: Zacks Research cut estimates for Q2 2026, Q1 2027, Q3 2027, FY2026, FY2027, FY2028, and Q1 2028, signaling a weaker near-term and medium-term earnings outlook. Perrigo estimate cuts
• Negative Sentiment: Perrigo’s most recent results showed revenue below expectations and sales down year over year, which can weigh on investor sentiment even though EPS came in ahead of estimates. Perrigo earnings results

Perrigo Price Performance

Shares of NYSE:PRGO opened at $11.03 on Monday. The company has a 50 day moving average of $10.97 and a 200 day moving average of $12.62. The stock has a market cap of $1.53 billion, a P/E ratio of -0.84, a P/E/G ratio of 1.30 and a beta of 0.51. Perrigo Company plc has a 12 month low of $9.23 and a 12 month high of $28.43. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company earned $0.60 EPS. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts forecast that Perrigo Company plc will post 2.12 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.5%. Perrigo’s dividend payout ratio is -8.85%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PRGO. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings lowered shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Finally, Canaccord Genuity Group lowered their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.